SCHEMBL27717232

SCHEMBL27717232

NC(=O)Oc1nc2ccc(O)cc2s1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.54
GAA P10253 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
CA1 P00915 2/20 0.51
CA2 P00918 2/20 0.51
CA12 O43570 1/20 0.51
CA4 P22748 1/20 0.51
CA6 P23280 1/20 0.51
CA5A P35218 1/20 0.51
CA9 Q16790 1/20 0.51
CA14 Q9ULX7 1/20 0.51
CA5B Q9Y2D0 1/20 0.51
DYRK1A Q13627 2/20 0.49
HSD17B1 P14061 8/20 0.48
HSD17B2 P37059 7/20 0.48
APP P05067 2/20 0.47
DYRK1B Q9Y463 1/20 0.44
SULT1A1 P50225 3/20 0.43
MAOB P27338 2/20 0.43
CYP1A2 P05177 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28664679 0.84 SMN1; SMN2 (0.50) GAACA1CA2CA4APP
SCHEMBL3709201 0.83 RAB9A (0.51) HTTDYRK1AAPPCYP1A2CYP3A4
SCHEMBL6632291 0.79 CYP1A2 (0.54) GAACA1CA2CA12CA4
SCHEMBL29248357 0.79 ALDH1A1 (0.44) GAACA1CA2CA12CA9
SCHEMBL28930490 0.79 ALDH1A1 (0.59) HTTCA2CA5ADYRK1ACYP3A4
SCHEMBL23249736 0.77 GAA (0.47) HTTGAAL3MBTL1DYRK1AAPP
SCHEMBL28588889 0.77 NPC1 (0.60) GAACA1CA2CA12DYRK1A
SCHEMBL27689304 0.77 DYRK1A (0.49) HTTGAAL3MBTL1CA1CA2
SCHEMBL2763498 0.76 CYP2C9 (0.36) CA2CA5ADYRK1ACYP1A2CYP3A4
SCHEMBL20509400 0.76 L3MBTL1 (0.51) HTTGAAL3MBTL1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101273019-A Novel benzimidazole and benzothiazole derivatives, method for preparing same, use thereof as drugs, pharmaceutical compositions and novel use especially as C-Met inhibitors AVENTIS PHARMA SA (FR) 2008-09-24 CN disclosed